Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $12.19 and traded as high as $12.89. Reckitt Benckiser Group shares last traded at $12.79, with a volume of 303,510 shares changing hands.
Analyst Ratings Changes
RBGLY has been the subject of a number of recent analyst reports. UBS Group upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research report on Wednesday, September 18th. Citigroup raised Reckitt Benckiser Group to a "strong-buy" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a research report on Thursday, August 29th. Finally, Barclays upgraded Reckitt Benckiser Group to a "strong-buy" rating in a report on Friday, October 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy".
Get Our Latest Report on RBGLY
Reckitt Benckiser Group Stock Up 0.7 %
The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97. The company has a 50-day moving average price of $12.22 and a 200-day moving average price of $11.56.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
